Brands, Medical Use, Clinical Data
Brands / Synonyms
AntiCD20; Ig gamma-1 chain C region; Rituxan; Rituxan (Genentech Inc)
Rituxan is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light- and heavy-chain variable region sequences and human constant region sequences. Rituximab is composed of two heavy chains of 451 amino acids and two light chains of 213 amino acids
For treatment of B-cell non-Hodgkins lymphoma (CD20 positive)
Rituxan binds to the CD20 antigen, which is predominantly expressed on mature B cells and on >90% of B-cell
non-Hodgkin's lympohomas. The antibody leads to selective killing of B-cells.
Mechanism of Action
Binds to the CD20 antigen which is found on mature B lymphocytes. The Fc domain recruits immune effector functions to mediate B-cell lysis. The antibody appears to induce apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
Biotrnasformation / Drug Metabolism
Most likely removed by opsonization via the reticuloendothelial system when bound to B lymphocytes, or by human antimurine antibody production